Meropenem

C difficile risk
Medium
Oral Bioavailability
N/A

Dosing

  • Standard Dose: 500mg IV q6h (over 3-hr) -or- 500 mg q6h - 1g IV q8h (over 30-min)

  • Meningitis: 2g IV q8h (over 3-hr or 30-min)

CrCl 0 - 10 CrCl 10 - 29CrCl 30 - 50 CrCl > 50 - Standard Dose: 500mg IV q24h (over 3-hr or 30-min)

  • Meningitis: 1g IV q24h (over 3-hr or 30-min)- Standard Dose: 500mg IV q12h (over 3-hr or 30-min)

  • Meningitis: 1g IV q12h (over 3-hr or 30-min)- Standard Dose: 500mg IV q8h (over 3-hr) -or- 500 mg q8h - 1g IV q12h (over 30-min)

  • Meningitis: 2g IV q12h (over 3-hr or 30-min)Usual dosing

  • Standard Dose: 500mg IV q24h (over 3-hr or 30-min)

  • Meningitis: 1g IV q24h (over 3-hr or 30-min)

500 mg - 1 g IV q8h (over 3-hr or 30-min)

General Information

Therapy of serious, often nosocomial infections involving resistant gram negative organisms

  •  Immediate and delayed-type allergy

  •  GI disturbance

  •  Cytopenias, positive Coombs

  •  Liver enzyme abnormalities

Valproic acid - Carbapenems decrease valproate levels and may decrease seizure threshold

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 1 hour

Urine penetration: Therapeutic

Lung penetration: Therapeutic

CSF penetration: Moderate

Biliary penetration: Therapeutic

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.